periprosthetic joint infection

Dallas Biotech Secures $50M Series D Funding To Combat Rare Hidden Killer in Joint Replacements

by | Jul 16, 2024
The $50 million funding will support the commercial launch of Osteal Therapeutics' pioneering combination drug/device therapy targeting biofilm infections, which are notoriously difficult to eradicate.
MORE